Drug Profile
Research programme: proto oncogene proteins c-akt inhibitors - Astex/Institute of Cancer Research/Cancer Research Technology
Alternative Names: AT 11854; AT 7867; CCT 128930; CCT 129254; CCT077373; CCT077933Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
- Developer Astex Pharmaceuticals; Cancer Research UK; The Institute of Cancer Research
- Class Benzamides; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
- 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen